Mora S - Search Results

1

Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children.

Viganò A, Mora S, Testolin C, Beccio S, Schneider L, Bricalli D, Vanzulli A, Manzoni P, Brambilla P. Viganò A, et al. Among authors: mora s. J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):482-9. doi: 10.1097/00126334-200304150-00003. J Acquir Immune Defic Syndr. 2003. PMID: 12679698

2

Adverse effects of antiretroviral therapy: focus on bone density.

Viganò A, Mora S. Viganò A, et al. Among authors: mora s. Expert Opin Drug Saf. 2004 May;3(3):199-208. doi: 10.1517/14740338.3.3.199. Expert Opin Drug Saf. 2004. PMID: 15155148 Review.

3

Effects of recombinant growth hormone on visceral fat accumulation: pilot study in human immunodeficiency virus-infected adolescents.

Viganò A, Mora S, Manzoni P, Schneider L, Beretta S, Molinaro M, di Natale B, Brambilla P. Viganò A, et al. Among authors: mora s. J Clin Endocrinol Metab. 2005 Jul;90(7):4075-80. doi: 10.1210/jc.2004-2431. Epub 2005 Apr 19. J Clin Endocrinol Metab. 2005. PMID: 15840750

4

A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children.

Giacomet V, Mora S, Martelli L, Merlo M, Sciannamblo M, Viganò A. Giacomet V, et al. Among authors: mora s. J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):448-50. doi: 10.1097/01.qai.0000184860.62189.c8. J Acquir Immune Defic Syndr. 2005. PMID: 16280700

5

Applicability of quantitative ultrasonography of the radius and tibia in HIV-infected children and adolescents.

Mora S, Viganò A, Cafarelli L, Pattarino G, Giacomet V, Gabiano C, Mignone F, Zuccotti G. Mora S, et al. J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):588-92. doi: 10.1097/QAI.0b013e3181adc838. J Acquir Immune Defic Syndr. 2009. PMID: 19502989

6

Impaired growth hormone secretion correlates with visceral adiposity in highly active antiretroviral treated HIV-infected adolescents.

Viganò A, Mora S, Brambilla P, Schneider L, Merlo M, Monti LD, Manzoni P. Viganò A, et al. Among authors: mora s. AIDS. 2003 Jul 4;17(10):1435-41. doi: 10.1097/00002030-200307040-00003. AIDS. 2003. PMID: 12824780

7

Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy.

Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Viganò A. Mora S, et al. AIDS. 2001 Sep 28;15(14):1823-9. doi: 10.1097/00002030-200109280-00011. AIDS. 2001. PMID: 11579244

8

Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children.

Mora S, Zamproni I, Beccio S, Bianchi R, Giacomet V, Viganò A. Mora S, et al. J Clin Endocrinol Metab. 2004 Jan;89(1):24-8. doi: 10.1210/jc.2003-030767. J Clin Endocrinol Metab. 2004. PMID: 14715822 Free article.

9

Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children.

Viganò A, Aldrovandi GM, Giacomet V, Merlo M, Martelli L, Beretta S, Luraschi P, Rombolà G, Mora S. Viganò A, et al. Among authors: mora s. Antivir Ther. 2005;10(8):917-24. Antivir Ther. 2005. PMID: 16430197 Clinical Trial.

10

Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz.

Viganò A, Brambilla P, Cafarelli L, Giacomet V, Borgonovo S, Zamproni I, Zuccotti G, Mora S. Viganò A, et al. Among authors: mora s. Antivir Ther. 2007;12(3):297-302. Antivir Ther. 2007. PMID: 17591019 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

723 results

Search Page

Filters